{"url_path":"/sec/jagx/8-k/2026-05-19/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1585608/0001193125-26-231083-index.html","accession_number":"0001193125-26-231083","cik":"0001585608","ticker":"JAGX","issuer_name":"Jaguar Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1585608/0001193125-26-231083-index.html","primary_entity_key":"0001585608","primary_entity_name":"Jaguar Health, Inc."},"word_count":109,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNo.\n\n  \nDescription\n\n 3.1\n  \n[Certificate of Designation of Preferences, Rights and Limitations of Series Q Convertible Preferred Stock.](d227929dex31.htm)\n\n10.1\n  \n[Uptown Series Q Exchange Agreement.](d227929dex101.htm)\n\n10.2\n  \n[First Streeterville Series Q Exchange Agreement.](d227929dex102.htm)\n\n10.3\n  \n[Second Streeterville Series Q Exchange Agreement.](d227929dex103.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nJAGUAR HEALTH, INC.\n\nDate: May 19, 2026\n \n\n \nBy:\n \n\n/s/ Lisa A. Conte\n\n \n\n \n\n \nLisa A. Conte\n\n \n\n \n\n \nChief Executive Officer & President"}